(IN BRIEF) GSK has received approval from China’s National Medical Products Administration for Nucala as an add-on maintenance therapy for adults with inadequately controlled COPD and elevated blood eosinophils. Supported by positive MATINEE and METREX phase III trial data, the … Read the full press release →
Posted in Business, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biologic therapy, blood eosinophil count, China Approves GSK’s Nucala to Reduce Exacerbations in Adults with COPD, China NMPA approval, Chronic obstructive pulmonary disease, COPD treatment, eosinophilic COPD, exacerbation reduction, GSK, IL-5 monoclonal antibody, Kaivan Khavandi, MATINEE trial, mepolizumab, METREX trial, Nucala, respiratory medicine
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
